Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects.
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid β1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid β1-42 levels within the normal range into account. Ann Neurol 2017;81:749-753.
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.
Betty M
BM
Tijms
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.
Daniela
D
Bertens
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.
Rosalinde E
RE
Slot
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.|Department of Clinical Neurophysiology/MEG Center, VU University Medical Center, Amsterdam, the Netherlands.
Alida A
AA
Gouw
Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, the Netherlands.
Charlotte E
CE
Teunissen
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.
Philip
P
Scheltens
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.|Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.
Wiesje M
WM
van der Flier
Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.|Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Pieter Jelle
PJ
Visser
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011379:Prognosis
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)